Functional interrogation of paramyxovirus genomes with efficient reverse genetics
通过有效的反向遗传学对副粘病毒基因组进行功能询问
基本信息
- 批准号:8973532
- 负责人:
- 金额:$ 20.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-12-01 至 2016-11-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdherenceAttenuatedAttenuated Live Virus VaccineAttenuated VaccinesBiologyCell LineCellsClinicalCodon NucleotidesComplementary DNACoupledCustomDevelopmentElectroporationEngineeringEnsureEventExhibitsGenerationsGenesGeneticGenetic RecombinationGenomeGenomicsGlycine decarboxylaseHealthHumanInsertional MutagenesisLibrariesLifeMediatingMethodologyMethodsMolecularMorbidity - disease rateMutagenesisNucleotidesParamyxoviridaeParamyxovirinaeParamyxovirusPathogenesisPlasmidsPolymeraseProductionProteinsRNA VirusesRabies virusReagentRecombinantsReportingResearchResearch PersonnelSendai virusSystemT7 RNA polymeraseTranscriptTransfectionVaccinia virusVacciniumViralViral GenesViral GenomeViral VaccinesVirusVirus DiseasesWorkattenuationbaseburden of illnesscytotoxiccytotoxicitydesigngene functiongenome-widehammerhead ribozymehigh throughput analysisimprovedmortalityparamyxovirus vaccinepathogenpressurepromoterresearch studyreverse geneticstissue culturetoolvaccine candidatevaccine developmentvector
项目摘要
DESCRIPTION (provided by applicant): Reverse genetics or de novo generation of infectious virus entirely from cloned cDNA is an invaluable tool for rescuing recombinant live-attenuated vaccine strains for many paramyxoviruses (PVs) that cause significant morbidity and mortality, and is indispensable for basic studies on PV biology. Despite these advances, reverse genetics systems for most paramyxoviruses (PVs) have remained notoriously inefficient for the past 15 years. Rescue efficiency, when documented, is ~1 in 106-107 transfected cells. This is a limiting barrier. Reverse genetics for paramyxoviruses require an exacting combination of viral support plasmids, a T7-promoter driven viral antigenome, and an abundant supply of T7RNAP, usually provided by recombinant vaccinia expressing T7RNAP (rVV-T7RNAP), or in some cases, by cell lines stably expressing T7RNAP. Neither strategy is compatible with making recombinant live-attenuated virus vaccine candidates for human trials, which requires GMP compliant cell lines, conditions and reagents. To overcome these many issues, we have custom- designed a codon-optimized T7 polymerase (T7opt) gene that enables the rescue of rPVs entirely from cloned cDNAs using a single-step transfection methodology. This method was used to rescue representative viruses from all five major Paramyxovirinae genera. The use of T7opt makes efficient rescue of PVs possible without rVV-T7RNAP. Rescue efficiency was further enhanced, up to 3-4 logs in some cases (~1 in 103 transfected cells), with the addition of a hammerhead ribozyme (Hh-Rbz) sequence in the transcribed antigenome. We engineered the activity and placement of this Hh-Rbz to ensure adherence to the "rule of six" by pre-designed autocatalytic cleavage of the transcript-initiating 3Gs derived from the full T7 promoter. Our T7opt-HhRbz methodology is faster, safer, more efficient, and allows the possibility of easy adaptation to GMP compliant conditions. Our objective is to leverage the transformative improvement in rescue efficiencies provided by our highly efficient T7opt-HhRbz system to functionally interrogate and explore a previously inaccessible phenotypic and genetic landscape in PV biology. In so doing, we also hope to broaden the range of attenuation options and molecular tools available to the broader field of researchers working on developing live-attenuated paramyxovirus vaccines. We proposed the following Specific Aims to fulfill our stated objective: AIM 1. Explore additional strategies to further enhance the rescue efficiency and robustness of our T7opt- HhRbz system in order to ensure the broadest applicability of our reverse genetics system. Additional improvements will facilitate attenuated vaccine development, and enable higher throughput analysis of the experiments in AIM 2, which is to functionally interrogate select Paramyxovirinae genomes using insertional mutagenesis. Our strategy utilizes the rule of six to our advantage while our high efficiency T7opt- HhRbz based rescue makes this aim feasible. We will interrogate the phenotypic landscape of our insertional mutagenesis library with a set of biologically relevant selective pressures.
描述(申请人提供):完全从克隆的cDNA反向遗传学或从头产生传染性病毒是拯救许多引起严重发病率和死亡率的副粘病毒(PV)的重组减毒活疫苗株的宝贵工具,并且对于PV生物学的基础研究是不可或缺的。尽管取得了这些进展,但在过去的15年里,大多数副粘病毒(PV)的反向遗传学系统仍然效率低下。当记录在案时,106-107转基因细胞的拯救效率为~1。这是一个限制障碍。副粘病毒的反向遗传学需要病毒支持质粒、T7启动子驱动的病毒抗基因组和充足的T7RNAP供应的严格组合,通常由表达T7RNAP的重组痘苗(rVV-T7RNAP)提供,在某些情况下,由稳定表达T7RNAP的细胞系提供。这两种策略都不适用于制造用于人体试验的重组减毒活疫苗候选疫苗,这需要符合GMP的细胞系、条件和试剂。为了克服这些问题,我们定制了一种密码子优化的T7聚合酶(T7opt)基因,它能够使用一步转染法将RPV完全从克隆的cDNA中拯救出来。这种方法被用来从所有五个主要的副粘病毒属中拯救具有代表性的病毒。T7opt的使用使得在没有rVV-T7RNAP的情况下有效地抢救静脉曲张成为可能。在转录的抗基因组中加入锤头状核酶(HH-RBZ)序列,进一步提高了拯救效率,在某些情况下可达到3-4logs(103个转基因细胞中~1个)。我们设计了这个HH-RBZ的活性和位置,以确保通过预先设计的自动催化切割来自完整的T7启动子的转录启动3GS来遵守“六规则”。我们的T7opt-HhRbz方法更快、更安全、更高效,并允许轻松适应符合GMP的条件。我们的目标是利用我们的高效T7opt-HhRbz系统在救援效率方面的革命性改进,从功能上询问和探索光伏生物学中以前无法进入的表型和遗传景观。通过这样做,我们还希望为致力于开发减毒副粘病毒活疫苗的更广泛领域的研究人员提供更广泛的减毒选择和分子工具。为了实现我们的既定目标,我们提出了以下具体目标:目标1.探索其他策略,以进一步提高我们的T7opt-HhRbz系统的救援效率和健壮性,以确保我们的反向遗传学系统的最广泛适用性。额外的改进将促进减毒疫苗的开发,并使AIM 2中的实验能够进行更高的吞吐量分析,该实验将使用插入突变从功能上询问选定的副粘病毒基因组。我们的战略利用六规则对我们有利,而我们基于T7opt-HhRbz的高效率救援使这一目标变得可行。我们将用一组生物学上相关的选择压力来询问我们的插入突变文库的表型图景。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
Crystal structure and solution state of the C-terminal head region of the narmovirus receptor binding protein.
- DOI:10.1128/mbio.01391-23
- 发表时间:2023-10-31
- 期刊:
- 影响因子:6.4
- 作者:
- 通讯作者:
Sendai virus, an RNA virus with no risk of genomic integration, delivers CRISPR/Cas9 for efficient gene editing.
- DOI:10.1038/mtm.2016.57
- 发表时间:2016
- 期刊:
- 影响因子:0
- 作者:Park A;Hong P;Won ST;Thibault PA;Vigant F;Oguntuyo KY;Taft JD;Lee B
- 通讯作者:Lee B
Fitness selection of hyperfusogenic measles virus F proteins associated with neuropathogenic phenotypes
- DOI:10.1073/pnas.2026027118
- 发表时间:2021-05-04
- 期刊:
- 影响因子:11.1
- 作者:Ikegame, Satoshi;Hashiguchi, Takao;Lee, Benhur
- 通讯作者:Lee, Benhur
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Benhur Lee其他文献
Benhur Lee的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Benhur Lee', 18)}}的其他基金
Project 3 – Direct-Acting Antivirals against Paramyxoviruses
项目 3 — 针对副粘病毒的直接作用抗病毒药物
- 批准号:
10513944 - 财政年份:2022
- 资助金额:
$ 20.88万 - 项目类别:
Tropism, pathogenicity, and potential for zoonotic spillover of emergent henipa- and henipa-like viruses
新出现的亨尼帕病毒和亨尼帕样病毒的趋向性、致病性和人畜共患病溢出的可能性
- 批准号:
9749970 - 财政年份:2016
- 资助金额:
$ 20.88万 - 项目类别:
SUMO and ubiquitin modifications in henipavirus matrix trafficking and function
亨尼帕病毒基质运输和功能中的相扑和泛素修饰
- 批准号:
9159123 - 财政年份:2016
- 资助金额:
$ 20.88万 - 项目类别:
Platforms for structure-function studies of entry and budding of viral zoonotic
人畜共患病毒进入和出芽的结构功能研究平台
- 批准号:
8260253 - 财政年份:2011
- 资助金额:
$ 20.88万 - 项目类别:
Quantifying differential CD4 and CCR5 usage patterns amongst HIV-1/SIV strains
量化 HIV-1/SIV 毒株中 CD4 和 CCR5 使用模式的差异
- 批准号:
8026514 - 财政年份:2010
- 资助金额:
$ 20.88万 - 项目类别:
Quantifying differential CD4 and CCR5 usage patterns amongst HIV-1/SIV strains
量化 HIV-1/SIV 毒株中 CD4 和 CCR5 使用模式的差异
- 批准号:
8079510 - 财政年份:2010
- 资助金额:
$ 20.88万 - 项目类别:
Broad spectrum therapeutics that target the viral membrane
针对病毒膜的广谱疗法
- 批准号:
8071133 - 财政年份:2009
- 资助金额:
$ 20.88万 - 项目类别:
Platforms for structure-function studies of entry and budding of viral zoonotic
人畜共患病毒进入和出芽的结构功能研究平台
- 批准号:
7675173 - 财政年份:2009
- 资助金额:
$ 20.88万 - 项目类别:
Broad spectrum therapeutics that target the viral membrane
针对病毒膜的广谱疗法
- 批准号:
7645244 - 财政年份:2009
- 资助金额:
$ 20.88万 - 项目类别:
Broad spectrum therapeutics that target the viral membrane
针对病毒膜的广谱疗法
- 批准号:
8260871 - 财政年份:2009
- 资助金额:
$ 20.88万 - 项目类别:
相似海外基金
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 20.88万 - 项目类别:
Standard Grant
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 20.88万 - 项目类别:
Operating Grants
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 20.88万 - 项目类别:
Grant for R&D
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 20.88万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 20.88万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 20.88万 - 项目类别:
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 20.88万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 20.88万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 20.88万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 20.88万 - 项目类别:
Fellowship Programs














{{item.name}}会员




